How to access Vyndaqel from the UAE — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE patient diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) — wild-type or hereditary — may receive a prescription for Vyndaqel (tafamidis) from their treating cardiologist or heart-failure specialist. Vyndaqel is FDA-approved for ATTR-CM to reduce cardiovascular mortality and cardiovascular-related hospitalisation. It is manufactured by Pfizer. In the UAE, Vyndaqel access through the local supply chain is inconsistent for this indication, and patients are often routed through the named-patient import pathway when their cardiology team determines the therapy is clinically indicated.

This guide explains the legal pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Vyndaqel is an oral transthyretin (TTR) stabiliser taken once daily. By binding to circulating TTR tetramers, it slows the dissociation step that precedes amyloid fibril deposition in the myocardium. Eligibility is anchored to a confirmed ATTR-CM diagnosis — typically scintigraphy (PYP / DPD bone-tracer imaging) with or without endomyocardial biopsy, plus exclusion of AL amyloidosis and, where indicated, genetic testing to distinguish hereditary from wild-type disease. Your cardiologist will establish baseline NYHA class, NT-proBNP, and troponin, and will set a follow-up cadence. Vyndaqel is oral, well-tolerated, and does not require infusion infrastructure — the bottleneck is supply, not administration.

Is Vyndaqel legally importable into the UAE?

Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority operated by the Department of Health (DoH) in Abu Dhabi and the Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits.

The named-patient mechanism permits a UAE-licensed physician to import a medicine not otherwise routinely stocked when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally available alternative suits the specific patient, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented end-to-end. ATTR-CM has limited disease-specific alternatives on UAE formularies, which simplifies the clinical rationale.

How the pathway works, step by step

1. Consultation with your treating cardiologist. Documentation of ATTR-CM diagnosis, scintigraphy evidence, AL-exclusion workup, and a clinical rationale letter.
2. Baseline assessment. NYHA class, NT-proBNP, troponin, eGFR, and a genetic test result (if hereditary ATTR is suspected) are captured.
3. MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing plan, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Vyndaqel from authorised distribution under DSCSA.
5. Ambient shipment. Vyndaqel capsules ship under controlled ambient conditions with chain-of-custody documentation.
6. Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with the neurology/cardiology-guided monitoring schedule.

What documentation your physician needs

• Clinical rationale letter confirming ATTR-CM diagnosis and Vyndaqel as the indicated therapy
• Verification of UAE medical license
• Copy of PYP/DPD scintigraphy report; endomyocardial biopsy report where available
• AL-exclusion workup (serum/urine immunofixation, free light chains)
• Baseline NYHA, NT-proBNP, eGFR
• Hereditary-ATTR genetic report if relevant
• Planned dosing schedule (daily oral) and annual follow-up plan

Reserve Meds provides a physician documentation kit bundling the templates MoHAP reviewers expect for cardiology named-patient imports.

Costs and timing

Vyndaqel's US cash-pay reference cost for ATTR-CM sits in an indicative 2026 annual range of roughly USD 225,000–275,000. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted. Refills ship on a rolling monthly schedule.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Vyndaqel we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for MoHAP review.
• Logistics. Ambient-controlled shipment with chain-of-custody to the prescribing hospital pharmacy.
• Concierge case lead. A named point of contact coordinating long-term monthly refills.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.

What if scintigraphy is equivocal? Your cardiologist may pursue endomyocardial biopsy or repeat imaging. MoHAP reviewers expect the diagnostic evidence to be clear before approving a named-patient import; Reserve Meds can hold your intake pending.

Does Vyndaqel treat the polyneuropathy form of ATTR? The related Vyndamax (20 mg tafamidis) and other transthyretin-silencer therapies (Amvuttra, Wainzua) address polyneuropathy — your neurologist/cardiologist team will select the appropriate agent. We cover these pairs in adjacent guides.

Will insurance cover this? Cash-pay is the default. Some UAE private insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Vyndaqel coordination.

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.